ConductScience.org, home
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
API referenceFor AI assistants

Trial · NCT00528840

Results by group21

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 21

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Reduction in Contracture to 5° or LessAA4500 0.58 mg52.7percentage of joints
Clinical Improvement After the Last InjectionAA4500 0.58 mg71.6percent of joints
Percent Reduction From Baseline Contracture After the Last InjectionAA4500 0.58 mg66.8Standard Deviation 40.91percentage of joints
Change From Baseline Range of Motion After the Last InjectionAA4500 0.58 mg28.3Standard Deviation 20.15degrees
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 19.6percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 716.4percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 3016.1percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 00.0percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 12.4percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 72.4percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 303.1percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 00.0percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 10.7percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 71.0percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 300.7percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 900.3percentage of joints
Time to Reach Clinical SuccessAA4500 0.58 mgDid not reach clinical success47.3percentage of joints
Clinical Success After the First InjectionAA4500 0.58 mg42.5percentage of joints
Clinical Improvement After the First InjectionAA4500 0.58 mg64.4percentage of joints
Percent Reduction From Baseline Contracture After the First InjectionAA4500 0.58 mg60.4Standard Deviation 39.38percentage of change

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00528840/results

API referenceFor AI assistants